Company profile
UK company 11694429, incorporated on 23 November 2018.
Fibrofind Homepage
Fibrofind is a preclinical drug development powerhouse.
Company number 11694429
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AP01 | Transaction MzUzMDA0MDQxMmFkaXF6a2N4
Published 02 Jul 2026 09:35
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Fibrofind develops drugs and technology for the treatment of fibrotic diseases along with research tools such as in vivo disease models.
FibroFind is a Newcastle University spin-out company established by Profs Jelena Mann, Derek Mann, Fiona Oakley and Dr Lee Borthwick. The company holds intellectual property concerning the development of platforms for the culture, maintenance and induction of fibrosis in precision cut tissue slices. FibroFind provides a pre-clinical drug testing service to its clients from the pharmaceutical and biotechnology sectors who are working in the fibrosis field.
FibroFind currently employs 5 full-time and 4 part-time members of staff. A key client of FibroFind is the biotechnology company Hepion who it has worked with to help develop its NASH drug candidate CV431 which is currently in clinical studies. The following links provide details of the work carried out by FibroFind and its impact: https://www.globenewswire.com/news-release/2019/06/17/1869573/0/en/Compelling-Positive-Results-Reported-from-Human-Liver-Experiments-with-ContraVir-Pharmaceuticals-NASH-Drug-Candidate.html https://finance.yahoo.com/news/hepion-nash-drug-candidate-crv431-211500196.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvLnVrLw&guce_referrer_sig=AQAAADDp4U7kDSXN0Ja3ZV8oK5JUh4VvT75GY7rLEagW0ZrZ5QHlnQuXjMJm3Ln2HGgkPi5h2NIxpvqEtxHzggMbLOf4mc2aVWl-KUoOTXre6PfG1m1-0fZBqKMF7ydAazse4daZ8p3PRTXZ4rOwVIJxzgm1qpE78jf6B38buoKYu5vK
FibroFind currently employs 17 members of staff A key client of FibroFind is the biotechnology company Hepion who it has worked with to help develop its NASH drug candidate CV431 which is currently in clinical studies. The following links provide details of the work carried out by FibroFind and its impact: https://www.globenewswire.com/news-release/2019/06/17/1869573/0/en/Compelling-Positive-Results-Reported-from-Human-Liver-Experiments-with-ContraVir-Pharmaceuticals-NASH-Drug-Candidate.html https://finance.yahoo.com/news/hepion-nash-drug-candidate-crv431-211500196.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvLnVrLw&guce_referrer_sig=AQAAADDp4U7kDSXN0Ja3ZV8oK5JUh4VvT75GY7rLEagW0ZrZ5QHlnQuXjMJm3Ln2HGgkPi5h2NIxpvqEtxHzggMbLOf4mc2aVWl-KUoOTXre6PfG1m1-0fZBqKMF7ydAazse4daZ8p3PRTXZ4rOwVIJxzgm1qpE78jf6B38buoKYu5vK
